Malte W Vetterlein1,2, Stephanie A M Wankowicz3, Thomas Seisen1,4, Richard Lander1, Björn Löppenberg1,5, Felix K-H Chun2, Mani Menon6, Maxine Sun1, Justine A Barletta7, Toni K Choueiri3, Joaquim Bellmunt3, Quoc-Dien Trinh1, Mark A Preston1. 1. Division of Urological Surgery, Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 4. Department of Urology, Pitié-Salpêtriére Hospital, Pierre and Marie Curie University, Paris, France. 5. Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany. 6. Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan. 7. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, to the authors' knowledge, it is unknown whether this benefit persists in histological variants. The objective of the current study was to assess the effect of neoadjuvant chemotherapy on the probability of non-organ-confined disease and overall survival after radical cystectomy (RC) in patients with histological variants. METHODS: Querying the National Cancer Data Base, the authors identified 2018 patients with histological variants who were undergoing RC for bladder cancer between 2003 and 2012. Variants were categorized as micropapillary or sarcomatoid differentiation, squamous cell carcinoma, adenocarcinoma, neuroendocrine tumors, and other histology. Logistic regression models estimated the odds of non-organ-confined disease at the time of RC for each histological variant, stratified by the receipt of neoadjuvant chemotherapy. Cox regression models were used to examine the effect of neoadjuvant chemotherapy on overall mortality in each variant subgroup. RESULTS: Patients with neuroendocrine tumors (odds ratio [OR], 0.16; 95% confidence interval [95% CI], 0.08-0.32 [P<.001]), micropapillary differentiation (OR, 0.30; 95% CI, 0.10-0.95 [P=.041]), sarcomatoid urothelial carcinoma (OR, 0.40; 95% CI, 0.17-0.94 [P=.035]), and adenocarcinoma (OR, 0.24; 95% CI, 0.06-0.91 [P=.035]) were less likely to harbor non-organ-confined disease at the time of RC when treated with neoadjuvant chemotherapy. An overall survival benefit for neoadjuvant chemotherapy was only found in patients with neuroendocrine tumors (hazard ratio, 0.49; 95% CI, 0.33-0.74 [P=.001]). CONCLUSIONS: Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better overall survival and lower rates of non-organ-confined disease at the time of RC. For tumors with micropapillary differentiation, sarcomatoid differentiation, or adenocarcinoma, neoadjuvant chemotherapy decreased the frequency of non-organ-confined disease at the time of RC. However, this favorable effect did not translate into a statistically significant overall survival benefit for these patients, potentially due to the aggressive tumor biology. Cancer 2017;123:4346-55.
BACKGROUND: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, to the authors' knowledge, it is unknown whether this benefit persists in histological variants. The objective of the current study was to assess the effect of neoadjuvant chemotherapy on the probability of non-organ-confined disease and overall survival after radical cystectomy (RC) in patients with histological variants. METHODS: Querying the National Cancer Data Base, the authors identified 2018 patients with histological variants who were undergoing RC for bladder cancer between 2003 and 2012. Variants were categorized as micropapillary or sarcomatoid differentiation, squamous cell carcinoma, adenocarcinoma, neuroendocrine tumors, and other histology. Logistic regression models estimated the odds of non-organ-confined disease at the time of RC for each histological variant, stratified by the receipt of neoadjuvant chemotherapy. Cox regression models were used to examine the effect of neoadjuvant chemotherapy on overall mortality in each variant subgroup. RESULTS:Patients with neuroendocrine tumors (odds ratio [OR], 0.16; 95% confidence interval [95% CI], 0.08-0.32 [P<.001]), micropapillary differentiation (OR, 0.30; 95% CI, 0.10-0.95 [P=.041]), sarcomatoid urothelial carcinoma (OR, 0.40; 95% CI, 0.17-0.94 [P=.035]), and adenocarcinoma (OR, 0.24; 95% CI, 0.06-0.91 [P=.035]) were less likely to harbor non-organ-confined disease at the time of RC when treated with neoadjuvant chemotherapy. An overall survival benefit for neoadjuvant chemotherapy was only found in patients with neuroendocrine tumors (hazard ratio, 0.49; 95% CI, 0.33-0.74 [P=.001]). CONCLUSIONS:Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better overall survival and lower rates of non-organ-confined disease at the time of RC. For tumors with micropapillary differentiation, sarcomatoid differentiation, or adenocarcinoma, neoadjuvant chemotherapy decreased the frequency of non-organ-confined disease at the time of RC. However, this favorable effect did not translate into a statistically significant overall survival benefit for these patients, potentially due to the aggressive tumor biology. Cancer 2017;123:4346-55.
Authors: Luca Boeri; Matteo Soligo; Igor Frank; Stephen A Boorjian; R Houston Thompson; Matthew Tollefson; Robert Tarrel; Fernando J Quevedo; John C Cheville; R Jeffrey Karnes Journal: World J Urol Date: 2019-02-25 Impact factor: 4.226
Authors: Sean A Fletcher; Sabrina S Harmouch; Marieke J Krimphove; Alexander P Cole; Sebastian Berg; Philipp Gild; Mark A Preston; Guru P Sonpavde; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh Journal: World J Urol Date: 2018-06-14 Impact factor: 4.226
Authors: Jonathan J Duplisea; Firas G Petros; Roger Li; Bryan Fellman; Charles C Guo; Bogdan A Czerniak; Arlene O Siefker-Radtke; John C Araujo; Colin P N Dinney; Surena F Matin Journal: Urol Oncol Date: 2019-02-16 Impact factor: 3.498
Authors: Nima Almassi; Karissa Whiting; Antoun Toubaji; Andrew T Lenis; Emmet J Jordan; Helen Won; Ashley M Regazzi; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Samson W Fine; Satish K Tickoo; Irina Ostrovnaya; Eugene J Pietzak; Eugene K Cha; Alvin C Goh; Timothy F Donahue; Harry W Herr; S Machele Donat; Guido Dalbagni; Bernard H Bochner; Min Yuen Teo; Samuel A Funt; Jonathan E Rosenberg; Victor E Reuter; Dean F Bajorin; David B Solit; Hikmat Al-Ahmadie; Gopa Iyer Journal: JCO Precis Oncol Date: 2022-06
Authors: Nima Almassi; Emily A Vertosick; Daniel D Sjoberg; Nathan C Wong; Chun Huang; Eugene J Pietzak; Eugene K Cha; Timothy F Donahue; Guido Dalbagni; Bernard H Bochner; Gopa Iyer; Jonathan E Rosenberg; Dean F Bajorin; Hikmat Al-Ahmadie; Alvin C Goh Journal: BJU Int Date: 2021-05-24 Impact factor: 5.969